Prothena Corporation Shares Surge Despite Mixed Study Results

Shares of Prothena Corporation plc (NASDAQ:PRTA) surged 43% today, marking the most significant intraday rise since September 2022, despite the recent announcement regarding its Phase IIb PADOVA study, conducted by partner Roche. The study did not meet its primary endpoint in the trial for an experimental Parkinson’s disease drug.

Investor Optimism

Despite the missed endpoint, the stock's rise indicates investor optimism, potentially influenced by positive trends observed in the drug's development and anticipation of future potential.

The Dublin-based biotechnology firm revealed that the study of prasinezumab in patients with early-stage Parkinson’s disease showed:
– A numerical delay in motor progression
– Positive trends on multiple secondary and exploratory endpoints
– The drug was well tolerated with no new safety signals observed.

While the study did not meet its primary endpoint, it reported a hazard ratio (HR) of 0.84 and a p-value of 0.0657. Results were more pronounced in a pre-specified analysis of patients treated with levodopa—showing a nominal p-value of 0.0431.

Future Discussions

Prothena's President and CEO, Gene Kinney, Ph.D., stated that the PADOVA study results represent a significant step toward potentially delivering the first disease-modifying treatment for Parkinson’s disease. The company looks forward to discussions with health authorities on the most appropriate path forward.

Analyst Reactions

Analysts have provided mixed reactions to the news:
– BofA Securities analyst Tazeen Ahmad adjusted the price target on Prothena to $22.00 from $26.00, maintaining a Neutral rating, while expressing uncertainty about the program's future due to lack of definitive evidence after two failed phase 2 trials.
– Conversely, Oppenheimer analyst Jay Olson reduced the price target to $58.00 from $62.00 but maintained an Outperform rating, citing the upcoming AFFIRM-AL study as a significant catalyst.

In light of today's developments, BofA Securities noted, "Today’s data release could serve as a clearing event for investors who now shift focus to PRTA’s AL amyloidosis data readout – which is the biggest driver of our NPV for PRTA shares."

Broader Pipeline Potential

Investors seem to be responding positively to the potential of prasinezumab and Prothena’s broader pipeline, particularly with:
– Expected phase 3 readout of birtamimab in AL amyloidosis in the first half of 2025.
– Data updates for PRX012 in Alzheimer’s disease expected in mid-2025.

The full results from the PADOVA study will be presented at an upcoming medical meeting.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.